Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of <i>TP53</i> Alterations and Venetoclax Treatment

Abbas, Hussein A.; Ayoub, Edward; Sun, Hanxiao; Kanagal‐Shamanna, Rashmi; Short, Nicholas J.; Issa, Ghayas C.; Yılmaz, Musa; Pierce, Sherry; Rivera, Daniel; Cham, Brent; Wing, Shane; Li, Ziyi; Hammond, Danielle; Jabbour, Elias; Borthakur, Gautam; Andreeff, Michael; Daver, Naval; Kadia, Tapan M.; Konopleva, Marina; DiNardo, Courtney D.; Ravandi, Farhad

doi:10.1182/blood-2022-170458

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AML patients with TP53 abnormal exhibit resistance to conventional chemotherapy, resulting in short overall survival (OS) (median 5–9 months) and high relapse rate , 5,6 even after hematopoietic stem cell transplant (HSCT) 2 . So far, many small‐molecule activators in the mutant TP53 ‐triggered pathway and TP53 signaling pathway have provided not only challenges but also opportunities for target therapies.…”

Section: Introductionmentioning

confidence: 99%

TP53 signal pathway confers potential therapy target in acute myeloid leukemia

Zhu

Cai

Zhong

2023

European J of Haematology

View full text Add to dashboard Cite

TP53 mutation is a frequent tumor suppressor mutation and a critical prognostic indicator across studies in many malignant tumors including hematologic malignancies. However, the role of TP53 and its correlative pathway in acute myeloid leukemia (AML) is enigmatic, which may provide possible emerging strategies with the potential to improve outcomes in AML. Accordingly, we focus not only on the TP53 mutation but also on the underlying mechanisms of the mutated TP53 signal pathway. While it is now generally accepted that TP53 mutations are widely associated with a dismal prognosis, resistance to chemotherapy, and high incidence of relapse and refractory AML. Hereby, the current therapeutics targeting TP53 mutant AML are summarized in this review. This will address emerging TP53-based therapeutic approaches, facilizing the TP53-targeted treatment options.

show abstract

Section: Introductionmentioning

confidence: 99%